Table 4.
Multivariate analysis of prognostic factorsa affecting breast cancer death, distant disease, and locoregional recurrence by age
| <35 years | 35–39 years | 40–49 years | 50–69 years | ||||
|---|---|---|---|---|---|---|---|
| N = 445 | N = 190 | N = 192 | N = 293 | ||||
| Breast cancer death | |||||||
| Unadjusted | 2.75 | (1.93–3.94) | 2.33 | (1.54–3.52) | 1.53 | (0.97–2.39) | 1.00 (ref) |
| +Year | 2.69 | (1.88–3.85) | 2.23 | (1.48–3.38) | 1.45 | (0.92–2.28) | |
| +Stage | 1.80 | (1.25–2.60) | 1.42 | (0.93–2.17) | 1.13 | (0.72–1.78) | |
| +Detection mode | 1.39 | (0.93–2.07) | 1.10 | (0.70–1.72) | 0.94 | (0.59–1.50) | |
| +Grade | 1.16 | (0.77–1.73) | 0.94 | (0.59–1.49) | 0.85 | (0.53–1.36) | |
| +Subtype | 1.10 | (0.73–1.64) | 0.93 | (0.59–1.47) | 0.86 | (0.53–1.38) | |
| +Systemic treatment | 1.04 | (0.68–1.58) | 0.88 | (0.55–1.41) | 0.84 | (0.52–1.36) | |
| Distant disease | |||||||
| Unadjusted | 3.11 | (2.22–4.36) | 2.37 | (1.60–3.53) | 1.74 | (1.15–2.64) | 1.00 (ref) |
| +Year | 3.04 | (2.17–4.26) | 2.28 | (1.53–3.39) | 1.65 | (1.09–2.50) | |
| +Stage | 2.09 | (1.48–2.96) | 1.46 | (0.97–2.18) | 1.29 | (0.85–1.96) | |
| +Detection mode | 1.61 | (1.10–2.35) | 1.13 | (0.73–1.73) | 1.07 | (0.70–1.66) | |
| +Grade | 1.41 | (0.96–2.06) | 1.02 | (0.66–1.57) | 1.00 | (0.65–1.55) | |
| +Subtype | 1.40 | (0.96–2.05) | 1.01 | (0.65–1.55) | 1.00 | (0.65–1.55) | |
| +Systemic treatment | 1.36 | (0.91–2.02) | 0.97 | (0.62–1.52) | 0.99 | (0.64–1.54) | |
| Locoregional recurrence | |||||||
| Unadjusted | 3.16 | (1.98–5.04) | 2.88 | (1.70–4.89) | 1.94 | (1.11–3.41) | 1.00 (ref) |
| +Year | 3.09 | (1.94–4.94) | 2.80 | (1.65–4.78) | 1.85 | (1.05–3.25) | |
| +Stage | 2.88 | (1.79–4.64) | 2.60 | (1.52–4.45) | 1.78 | (1.01–3.15) | |
| +Detection mode | 2.38 | (1.37–4.12) | 2.15 | (1.18–3.93) | 1.58 | (0.87–2.86) | |
| +Grade | 2.11 | (1.21–3.67) | 1.96 | (1.07–3.59) | 1.50 | (0.82–2.72) | |
| +Subtype | 2.09 | (1.20–3.65) | 1.94 | (1.06–3.57) | 1.51 | (0.83–2.74) | |
| +Systemic treatment | 2.13 | (1.21–3.76) | 1.97 | (1.06–3.68) | 1.51 | (0.83–2.75) | |
Women with stage I–III breast cancer diagnosed 1992–2005 (N = 1120). Women age 50–69 serves as reference category. Hazard ratio (95 % confidence interval)
Bold values indicate statistical significance at the p < 0.05 level
aAdjusted for year of diagnosis (1992–1997, 1998–2002, 2003–2005), stage (tumor size 1–10, 11–20, ≥20 mm, missing and lymph node status; node neg, node pos), detection mode (screening or clinically detected), grade (Elston I, II, III, missing), subtype (Lum A, Lum B, Lum-Her2, Her2-pos, Triple-neg, unclassified), systemic treatment (chemotherapy and endocrine treatment including ovarian suppression)